Accredited InvestorsEmployee ShareholdersInstitutionsPrivate Companies Who We Serve Trading and Investing Data Solutions Private Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Browse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunities​Forge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All Insights Private Market Reports Market Insights Buying and Selling Pre-IPO​ All Reports​Private Market UpdatesForge Investment OutlookStartup News and Trends​Private Market Data and Analytics​Tech IPO Calendar for 2024​Private Market Explained​Buying Pre-IPO Shares​Selling Pre-IPO SharesGlossaryVideosFAQsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
Solutions
Insights
About
Who We Serve
Solutions
Trading and Investing
Institutional Trading
Individual Investing
Data Solutions
Private Asset Custody
Self-Directed IRA
Insights
Private Market Reports
Market Insights
Buying and Selling Pre-IPO​
About
Log In
Sign Up
Secondary Marketplace / Trade Private Companies / Buy and Sell Alumis Stock

Alumis Stock

alumis.comHealthcare / BioTech & PharmaFounded: 2021Funding to Date: $638.43MM

Alumis is a biotechnology company focused on developing treatments for autoimmune disease, and their goal is to create therapies that are more precise than currently available autoimmune or immune-mediated disease treatments. Alumis was founded in 2021 and is headquartered in San Francisco, CA. Through its data analytics platform, Alumis seeks to enable researchers to match the right patients to targets, molecules, and combinations so they can create the best possible outcomes.

Learn more about Alumis IPO

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to Alumis before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value

Powered by Forge Data

Access valuation and stock price for companies like Alumis before its IPO.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Alumis stock FAQs

plusminus

Can you buy Alumis stock?

You can no longer buy Alumis stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

How to buy Alumis stock?

To invest in a private company like Alumis through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)
  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Alumis stock?

You can no longer sell stock of Alumis on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

How to sell Alumis stock?

If you hold private company shares of Alumis - whether as an employee or an early investor - Forge can help you sell them.
  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Alumis stock on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Alumis a public company?

No, Alumis is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Alumis’ stock ticker symbol?

The ticker symbol of Alumis is ALMS.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.
Featured

Startup Trends: Companies to achieve notable funding rounds in Q1 2024

Alumis investors also invested in these private companies

Foresite Capital
Cormorant Asset Management
Ally Bridge Group
Samsara Biocapital
venBio
Lilly Asia Ventures
Piper Sandler
HBM Healthcare Investments
SR One Capital Management
Omega Funds
Matrix Capital Management
NexTech

Explore private companies in the BioTech & Pharma sector

Colossal Biosciences
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B
Altos Labs
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B
ADARx Pharmaceuticals
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$827.77MM
Cytonics
Sector
Healthcare / BioTech & Pharma
 
 
AI Therapeutics
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM
Egenesis
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$333.77MM
Apnimed
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$366.58MM
Pendulum Therapeutics
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM
BillionToOne
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.25B

Team

Management Team

Mark Bradley
Chief Development Officer
Martin Babler
Chief Executive Officer & President
John Schroer
Chief Financial Officer
David Zhang Ph.D
Chief Information Officer & Senior Vice President of Biometrics and Data Management
Roy Hardiman JD
Chief Business and Legal Officer & General Counsel
David Goldstein Ph.D
Chief Scientific Officer & Head of Chemistry, Manufacturing, and Controls
Jörn Drappa Ph.D
Chief Medical Officer

Board Members

Alan Colowick MD
Matrix Capital Management
James Tananbaum MD
Foresite Capital
Michael Rome Ph.D
Foresite Capital
Richard Gaster Ph.D
venBio
Srinivas Akkaraju Ph.D
Samsara BioCapital
Vikram Bajaj Ph.D
Foresite Capital
Alumis 03/06/2024

Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction

In a series C funding round led by Foresite Capital and others, Alumis closed a deal of $259 million in financing for their oral therapy development,
Fierce Biotech 03/06/2024

Alumis closes $259M series C in year's largest private biotech fundraise yet

In new series C funding, Alumis raised $259 million to launch a new immune therapy trial.
Browse More Insights
Trending Companies

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.